Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...
HKG: 2315
Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a...
Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has signed an evaluation...
Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has entered into a...
Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...
Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key...
Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...
Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan
On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...
Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109
China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...
Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia,...
Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has...
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...
Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs
Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research...
Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform
Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been...
Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models
A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership...
Biocytogen and BioCopy AG Collaborate on TCR-Mimic Antibody Development for Cancer Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced an evaluation...
Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South...
Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...
Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens
Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...